Celularity has gained FDA clearance for its investigational new drug application for its natural killer cell therapy CYNK-001 designed to treat glioblastoma multiforme. The company announced plans to launch their first-in-human clinical trial in the US to test CYNK-001 in patients with relapsed glioblastoma multiforme.
Celularity's IND cleared to assess glioblastoma multiforme therapy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.